Ypsomed Holding AG
SIX:YPSN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
292
437
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ypsomed Holding AG
Ypsomed Holding AG
Cost of Revenue
Ypsomed Holding AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ypsomed Holding AG
SIX:YPSN
|
Cost of Revenue
-CHf398.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Alcon AG
SIX:ALC
|
Cost of Revenue
-$4.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Coltene Holding AG
SIX:CLTN
|
Cost of Revenue
-CHf83.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Medartis Holding AG
SIX:MED
|
Cost of Revenue
-CHf42.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
IVF Hartmann Holding AG
SIX:VBSN
|
Cost of Revenue
-CHf68.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
Ypsomed Holding AG
Glance View
Ypsomed Holding AG is a Swiss-based medical technology company that has carved out a niche in the rapidly growing diabetes management and drug delivery market. Founded in 1984, the company initially focused on producing insulin delivery systems but has since expanded its portfolio to include sophisticated pens and pumps that facilitate self-administration of medications. With an emphasis on innovation and user-centered design, Ypsomed has positioned itself as a leader in the development of advanced delivery systems that cater to the evolving needs of patients and healthcare providers alike. The company’s strategic partnerships with pharmaceutical firms enhance its growth trajectory, underscoring its commitment to improving patient outcomes and fostering adherence to treatment regimens. As an investor, you’ll appreciate Ypsomed’s robust financial performance, characterized by consistent revenue growth and a solid balance sheet. The company not only serves a significant portion of the diabetic population but also capitalizes on the increasing demand for self-medication and chronic disease management solutions. With a keen focus on research and development, Ypsomed is well-prepared to leverage trends in digital health and personalized medicine. Its global market presence, combined with a dedication to sustainability and innovation, positions Ypsomed as a compelling investment opportunity in a healthcare sector that is both resilient and essential. Ultimately, Ypsomed's commitment to transforming healthcare through advanced technology makes it an appealing choice for investors looking to tap into the future of medical devices.
See Also
What is Ypsomed Holding AG's Cost of Revenue?
Cost of Revenue
-398.4m
CHF
Based on the financial report for Sep 30, 2024, Ypsomed Holding AG's Cost of Revenue amounts to -398.4m CHF.
What is Ypsomed Holding AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
Over the last year, the Cost of Revenue growth was -15%. The average annual Cost of Revenue growth rates for Ypsomed Holding AG have been -7% over the past three years , -6% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
